Dr. Johnson joined the UT Southwestern Medical Center faculty on July 1, 2010 as the Donald W. Seldin Distinguished Chair in Internal Medicine and Chairman of the Department of Internal Medicine. Prior to joining UT Southwestern he was a member of the faculty at the Vanderbilt University Medical School where he held the Cornelius A. Craig Chair of Medical & Surgical Oncology and served as the Director of the Division of Hematology and Medical Oncology and Deputy Director of the Vanderbilt-Ingram Cancer Center.
He is a Past Chair of the American Board of Internal Medicine (ABIM) Board of Directors. He is also Past Chair of the ABIM Medical Oncology Subspecialty Board and a Past President of the American Society of Clinical Oncology (ASCO). During his term as ASCO President he helped advance the organization’s quality of care activity known as the Quality Oncology Practice Initiative (QOPI) and was instrumental in establishing ASCO’s Cancer Survivorship Program. Dr. Johnson has served on the Food and Drug Administration’s Oncology Drug Advisory Committee, as chairman of the Thoracic Committee of the Eastern Cooperative Oncology Group and on the Board of Directors of the National Comprehensive Cancer Network, the International Association for the Study of Lung Cancer and the LiveSTRONG Foundation.
In 2020 Dr. Johnson stepped down as Chair of the Department of Internal Medicine and is currently a Professor in the Division of Hematology/Oncology. Dr. Johnson’s research interests involve understanding the biology of lung cancer and improving the treatment of this and other solid tumors. He played a role in the development of the new targeted drugs bevacizumab (Avastin) and erlotinib (Tarceva) both of which are now FDA-approved for the treatment of lung cancer. Dr. Johnson earned his medical degree from the Medical College of Georgia and received medical oncology training at Vanderbilt University.
- Medical School
- Medical College of Georgia (1976)
- Mary Imogene Bassett Hospital (1976), Internal Medicine
- University of South Alabama Medical Center (1979), Internal Medicine
- Vanderbilt University Medical Center (1983), Hematology Oncology
- Developmental therapeutics
- Lung cancer therapeutics
- Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.
- Wang SE, Yu Y, Criswell TL, Debusk LM, Lin PC, Zent R, Johnson DH, Ren X, Arteaga CL. Oncogene 2010 29 3335-48
- Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
- Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH J Clin Oncol 2008 26 1472-78
Lung Cancer, Principles & Practice.
Harvey I. Pass, David P. Carbone, David H. Johnson, John D. Minna, G. Scagliotti, Andrew T. Turrisi, eds. (Ed.) (2010). Philadelphia, Lippincott Williams & Wilkins
Textbook of Uncommon Cancer - 4th ed
D. Raghavan, C.D. Blanke, D.H. Johnson, P.L. Moots, G.H. Reaman, P.G. Rose, M.K. Sekeres; eds (Ed.) (2012). Hoboken, NJ, Wiley-Blackwell
Honors & Awards
- Giants in Cancer Care Award
- ASCO Distinguished Achievement Award
- College of Arts & Sciences Hall of Fame, University of Kentucky
- Master, American College of Physicians
- Chairman, American Board of Internal Medicine Board of Directors
- Established Investigator Award, CPRIT
- Association of American Physicians
- Distinguished Southern Oncologist Award, Southern Association of Oncology
- President, American Society of Clinical Oncology
- Alpha Omega Alpha
- American Association for Cancer Research
- American College of Physicians
- American Society of Clinical Oncology
- Association of American Physicians
- International Association for the Study of Lung Cancer